文献速递产科母胎医学

血管生成标志物对已确诊子痫前期女性的附加作用

The additive role of angiogenic markers for women with confirmed preeclampsia.
PubMed 文献 · Am J Obstet Gynecol · 2022-11-07

本研究为前瞻性队列的二次分析,纳入2009年7月至2012年6月美国波士顿产科分诊处≥20+0周疑似子痫前期患者1043例,评估可溶性fms样酪氨酸激酶-1/胎盘生长因子比值在已确诊子痫前期患者中的附加预后价值。结果显示比值>38独立关联2周内进展为重度子痫前期,≤38可良好排除,>85可良好纳入。

要点

  • 比值>38与2周内重度子痫前期独立相关,限制性定义OR 15.62,宽泛定义OR 14.56。
  • 比值≤38排除2周内重度子痫前期,阴性似然比≤0.16,<35周≤0.12。
  • 比值>85纳入2周内重度子痫前期,<35周阳性似然比8.20,≥35周6.00。

核心结论

  • 研究结果支持sFlt-1/PlGF比值在已确诊子痫前期患者中的预后价值,尤其有助于识别未来2周内可能进展和不太可能进展为重度特征的患者,以及可能最适合期待治疗和潜在门诊治疗的患者。
  • 研究结果支持将血管生成失衡纳入子痫前期定义,尤其在20-34+0周。

研究设计与样本

  • 本研究为前瞻性队列研究的二次分析,纳入2009年7月至2012年6月美国波士顿产科分诊处≥20+0周疑似子痫前期的患者。
  • 共纳入1043例患者,其中459例在20+0至34+6周就诊,584例在≥35+0周就诊;临床医生对sFlt-1/PlGF比值结果设盲。
  • 子痫前期诊断分别采用国际妊娠高血压研究学会限制性标准(≥20周新发高血压和蛋白尿)或宽泛母体标准(新发高血压伴蛋白尿或一个及以上相关母体终末器官并发症)。
  • 重度子痫前期采用美国妇产科医师学会2013年定义。

主要发现

  • 分诊时,25.8%的疑似子痫前期女性已符合国际妊娠高血压研究学会宽泛标准的子痫前期诊断,22.0%符合限制性标准。
  • 在调整孕龄的多变量分析中,sFlt-1/PlGF比值>38与2周内重度子痫前期独立相关,即使调整分诊时子痫前期诊断后仍显著:限制性定义OR 15.62(95%CI 8.91-27.40),宽泛定义OR 14.56(95%CI 8.30-25.56)。
  • sFlt-1/PlGF比值≤38在所有患者及符合限制性或宽泛子痫前期定义者中良好排除2周内重度子痫前期(阴性似然比≤0.16),主要由35周前比值性能驱动(阴性似然比≤0.12)。
  • sFlt-1/PlGF比值>85在疑似子痫前期女性中良好纳入2周内重度子痫前期:35周前阳性似然比8.20,35周后阳性似然比6.00;在已确诊子痫前期且<35周患者中纳入性能一般:限制性阳性似然比3.48,宽泛阳性似然比3.40。

关键数值与推荐

  • sFlt-1/PlGF比值阈值:≤38、>38、>85。
  • 比值>38与2周内重度子痫前期独立相关:限制性定义OR 15.62(95%CI 8.91-27.40),宽泛定义OR 14.56(95%CI 8.30-25.56)。
  • 比值≤38排除2周内重度子痫前期:阴性似然比≤0.16(所有患者及符合限制性或宽泛定义者),<35周阴性似然比≤0.12。
  • 比值>85纳入2周内重度子痫前期:<35周阳性似然比8.20,≥35周阳性似然比6.00;已确诊子痫前期且<35周阳性似然比限制性3.48、宽泛3.40。

临床怎么用

  • 作者认为,研究结果支持sFlt-1/PlGF比值在已确诊子痫前期患者中的预后价值,尤其有助于识别未来2周内可能进展和不太可能进展为重度特征的患者。
  • 作者认为,研究结果支持将血管生成失衡纳入子痫前期定义,尤其在20-34+0周。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hypertension complicates 2% to 8% of all pregnancies and is a leading cause of maternal and perinatal morbidity and mortality globally. Given the prognostic role that angiogenic markers play in evaluation of patients with "suspected preeclampsia," the International Society for the Study of Hypertension in Pregnancy incorporated angiogenic imbalance into the 2021 definition of preeclampsia. As women with "suspected preeclampsia" are a heterogeneous group, with some already meeting the diagnostic criteria for preeclampsia, we evaluated whether the soluble fms-like tyrosine kinase-1/placental growth factor ratio adds prognostic value among these women. OBJECTIVE: This study aimed to assess the additive value of soluble fms-like tyrosine kinase-1/placental growth factor ratio when the diagnostic criteria for preeclampsia have already been met. STUDY DESIGN: This was a secondary analysis of a prospective cohort study of patients presenting to obstetrical triage with suspected preeclampsia at ≥20+0 weeks' gestation from July 2009 to June 2012 in Boston, United States. Clinicians were masked to soluble fms-like tyrosine kinase-1/placental growth factor ratio results. Clinical records were reviewed for maternal and neonatal care and outcomes. The value of the soluble fms-like tyrosine kinase-1/placental growth factor ratio (≤38, >38, or >85) was assessed for identifying women at low or high risk of evolving into preeclampsia with severe features within 2 weeks of the triage visit, with preeclampsia with severe features being defined by the American College of Obstetricians and Gynecologists (2013 definition). Based on information in obstetrical triage, preeclampsia among triage patients was defined either by: (1) The International Society for the Study of Hypertension in Pregnancy "restrictive" criteria (ie, new-onset hypertension and proteinuria at ≥20 weeks), or (2) The International Society for the Study of Hypertension in Pregnancy "broad" maternal criteria (ie, new-onset hypertension with proteinuria or one/more relevant maternal end-organ complications). RESULTS: Of 1043 patients included, 459 presented at 20+0 to 34+6 weeks and 584 at ≥35+0 weeks. In triage, 25.8% of women with "suspected preeclampsia" already met the preeclampsia criteria based on the International Society for the Study of Hypertension in Pregnancy broad criteria and 22.0% based on the restrictive criteria. In separate multivariable analyses adjusted for gestational age, a soluble fms-like tyrosine kinase-1/placental growth factor ratio >38 was independently associated with preeclampsia with severe features within 2 weeks even after adjusting for preeclampsia diagnosis in obstetrical triage, whether that preeclampsia were defined restrictively (odds ratio, 15.62; 95% confidence interval, 8.91-27.40) or broadly (odds ratio, 14.56; 95% confidence interval, 8.30-25.56). A soluble fms-like tyrosine kinase-1/placental growth factor ratio ≤38 was good at ruling out development of preeclampsia with severe features within 2 weeks among all patients and among those meeting the restrictive or broad definitions of preeclampsia (negative likelihood ratios, ≤0.16), driven by performance of the ratio before 35 weeks (ie, negative likelihood ratio ≤0.12). A soluble fms-like tyrosine kinase-1/placental growth factor ratio >85 was good at ruling-in preeclampsia with severe features within 2 weeks among women with suspected preeclampsia, either before (positive likelihood ratio, 8.20) or after 35 weeks (positive likelihood ratio, 6.00) and fair at ruling-in preeclampsia with severe features within 2 weeks when preeclampsia had already been confirmed in patients at <35 weeks (restrictively positive likelihood ratio, 3.48, or broadly positive likelihood ratio, 3.40). CONCLUSION: Our findings support the prognostic value of the soluble fms-like tyrosine kinase-1/placental growth factor ratio among patients with confirmed preeclampsia, particularly to identify those both likely and unlikely to progress toward the development of severe features in the next 2 weeks and those who may be most appropriate for expectant and potentially outpatient care. Our findings support the incorporation of angiogenic imbalance into the definition of preeclampsia, particularly at 20-34+0 weeks.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Suresh S, Patel E, Mueller A, et al. The additive role of angiogenic markers for women with confirmed preeclampsia. Am J Obstet Gynecol. 2022. PMID: 36356699. doi:10.1016/j.ajog.2022.10.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。